{"filing":{"accession_number":"0001753926-26-001109","cik":"0001266806","ticker":"VANI","company_name":"Vivani Medical, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"vani-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001109/vani-20260624.htm"},"events":[{"id":14846,"run_id":13236,"accession_number":"0001753926-26-001109","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The board adopted and stockholders approved an amendment to the 2022 Omnibus Incentive Plan increasing the share reserve by 11,000,000 shares, from 10,033,333 to 21,033,333 shares, expanding equity incentive capacity for officers and directors.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12407,"accession_number":"0001753926-26-001109","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02 discloses the board's adoption and stockholder approval of an amendment to the 2022 Omnibus Incentive Plan that increases the share reserve by 11,000,000 shares (from 10,033,333 to 21,033,333). This is a compensatory arrangement amendment affecting equity incentive capacity for officers and directors. While the supplemental exhibit discusses clinical trial approval, the Item 5.02 section itself focuses on the plan amendment, which is a classic exec_compensation disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":14847,"run_id":13236,"accession_number":"0001753926-26-001109","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Vivani held its Annual Meeting on June 24, 2026, with stockholders voting on and approving four proposals: election of six directors, advisory vote on named executive officer compensation, adoption of the 2022 Amended Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12408,"accession_number":"0001753926-26-001109","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Vivani's Annual Meeting held on June 24, 2026, including voting outcomes on four proposals: election of six directors, advisory vote on named executive officer compensation, adoption of the 2022 Amended Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities. This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and governance approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":14848,"run_id":13236,"accession_number":"0001753926-26-001109","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Vivani announced receipt of regulatory approval from Bellberry (an Australian human research ethics committee) to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant, representing a material clinical development milestone for the company's drug pipeline.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12409,"accession_number":"0001753926-26-001109","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Vivani announced receipt of regulatory approval from Bellberry (an Australian human research ethics committee) to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant. This is a material operational and regulatory milestone for a clinical-stage biopharmaceutical company—the approval clears the way for near-term trial initiation and represents progress in the company's drug development pipeline. While this is clearly a regulatory/operational event, it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named types; it is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12407,"accession_number":"0001753926-26-001109","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02 discloses the board's adoption and stockholder approval of an amendment to the 2022 Omnibus Incentive Plan that increases the share reserve by 11,000,000 shares (from 10,033,333 to 21,033,333). This is a compensatory arrangement amendment affecting equity incentive capacity for officers and directors. While the supplemental exhibit discusses clinical trial approval, the Item 5.02 section itself focuses on the plan amendment, which is a classic exec_compensation disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30"},{"id":12408,"accession_number":"0001753926-26-001109","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Vivani's Annual Meeting held on June 24, 2026, including voting outcomes on four proposals: election of six directors, advisory vote on named executive officer compensation, adoption of the 2022 Amended Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities. This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and governance approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30"},{"id":12409,"accession_number":"0001753926-26-001109","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Vivani announced receipt of regulatory approval from Bellberry (an Australian human research ethics committee) to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant. This is a material operational and regulatory milestone for a clinical-stage biopharmaceutical company—the approval clears the way for near-term trial initiation and represents progress in the company's drug development pipeline. While this is clearly a regulatory/operational event, it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named types; it is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:04:43.356231+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-06-30"}]}